Fondaparinux (Arixtra(R)), the first of a new class of antithrombotics - the synthetic selective factor Xa inhibitors - has been developed out of a, necessity for improvements in antithrombotics. In four large, double-blind, randomised studies in orthopaedic surgery, 1-week fondaparinux 2.5 mg showed a major benefit over enoxaparin (>50% risk reduction of venous thromboembolism [VTE]), without increasing clinically relevant bleeding. A recent study, PENTHIFRA Plus, evaluating extended prophylaxis with fondaparinux for 3 weeks after hip fracture surgery, showed a significant improvement in the rate Of total VTE (reduced from 35% to 1.4%), as well as symptomatic VTE (reduced from 2.7% to 0.3%). This VTE risk reduction was achieved without increasing the incidence of clinically relevant bleeding: In summary, 1-week fondaparinux demonstrated superiority over the approved regimens of enoxaparin in prevention of. VTE after major orthopaedic procedures, whereas 4-week fondaparinux showed a major, clinical benefit in patients, undergoing hip fracture surgery.